Abbott Laboratories Pakistan Limited · PSX:ABOT
Abbott Laboratories Pakistan — Investor Presentation (December 2022)
18 slides from Abbott Laboratories Pakistan's investor presentation, Dec 14, 2022
Slide 1: Corporate Briefing Session - 2022
Corporate Briefing Session - 2022 December 14th, 2022
Slide 2: Table of Contents
Table of Contents • Company Overview • Economic Overview • Financial Results for 2021 • Financial Results for Q3 2022 • Q&A
Slide 3: Company Overview
Company Overview Incorporated on July 02, 1948 1962 – Set up Other segments manufacturing Two manufacturing (mainly includes facility in Karachi general health and and listed as public facilities diabetes care) limited company in 1982 Abbott Laboratories (Pakistan) Limited 1,445 Employees Diagnostic
Slide 4: Pakistan – Macro Economic Overview
PAKISTAN – MACRO ECONOMIC OVERVIEW Gross Domestic Product Growth (GDP%) • GDP growth FY22 - registered 5.97% in FY22, rebounded from the pandemic (0.47% contraction in FY20) & continued to post 7% a V-Shaped economic recovery which is higher than 5.74% 5.74% 5.97% recorded in FY21 accompanied by ext
Slide 5: Inflow & Outflow
INFLOW & OUTFLOW CURRENT ACCOUNT DEFICIT 4M - FY23 USD IN BILLION Imports 4M-FY23: • Decreased by 12% from same period last year • Control Measures by SBP: Current Account 2.82 Deficit 5.31 ❖ Restriction on imports payments from July to date Workers' 9.90 ❖ Prior approvals for machineries, spare par
Slide 6: Foreign Exchange – USD / PKR Parity Round Up
FOREIGN EXCHANGE – USD / PKR PARITY ROUND UP USD/PKR Movement – 27% devaluation since Jan 2022 • Widening Current Account Deficit 239.65 239.37 • Control measures by SBP to curb FX outflow • Tightening monetary policy 221.92 224.40 • IMF program revived 211.48 217.79 • International assistance 213.9
Slide 7: Financial Results - 2021
Financial Results - 2021
Slide 8: Key Highlights – FY2021
Key Highlights – FY2021 • Overall revenue of the Company increased by 21% reaching Rs. 42.57 bn. Rs. 42.57bn 21% Sales Revenue Sales Growth • Increase in profitability mainly on account of price adjustments and product mix. • Earnings per share was Rs. 60.95 per share (2020: Rs. 46.33 per share). 38
Slide 9: Revenue Analysis – FY21
Revenue Analysis – FY21 Revenue Segment wise Revenue 44,000 42,570 42,000 21% (PKR in millions) PKR in million 40,000 38,000 36,000 35,283 Segment 2021 2020 % Increase 34,000 32,000 30,000 28,000 Pharmaceutical 27,578 23,877 16% 2020 2021 ➢ Pharmaceutical sales increased by 16% driven by performance
Slide 10: Segment Gross Profit analysis – FY21
Segment Gross Profit analysis – FY21 Segment GP 17,000 16,075 16,000 Segment-wise GP (PKR in millions) 15,000 36% 14,000 PKR in million 13,000 11,846 12,000 Segment 2021 GP % 2020 GP % 11,000 10,000 9,000 Pharmaceutical 10,008 36% 7,305 31% 2020 2021 Nutritional 4,646 46% 3,913 46% ➢ Segment profita
Slide 11: Financial Results – Q3 2022
Financial Results – Q3 2022
Slide 12: Key Highlights – Q3 2022
Key Highlights – Q3 2022 • Overall revenue of the Company increased by 18% reaching Rs. 36.95 bn. Rs. 36.95bn 18% • Sales increased on account of Sales Revenue Sales Growth volume by 10% and price by 8%. • Increase in product costs on account of Rupee devaluation and inflation has affected gross pro
Slide 13: Revenue Analysis – Q3 2022
Revenue Analysis – Q3 2022 Revenue 36,951 37,000 Segment wise Revenue 35,500 18% 34,000 (PKR in millions) PKR in million 32,500 31,447 31,000 29,500 Jan - Sep Jan - Sep 28,000 Segment % Inc 2022 2021 26,500 25,000 Q3 2021 Q3 2022 Pharmaceutical 23,282 20,131 16% ➢ Pharmaceutical sales increased on a
Slide 14: Segment Gross Profit analysis – Q3 2022
Segment Gross Profit analysis – Q3 2022 Segment GP 14,000 12,000 12,132 12,102 Segment-wise GP (PKR in millions) 10,000 PKR in million 8,000 Jan - Sep Jan - Sep 6,000 Segment 2022 GP % 2021 GP % 4,000 2,000 Q3 2021 Q3 2022 Pharmaceutical 7,472 32% 7,378 37% ➢ Absolute GP remained stagnant despite 18
Slide 15: Statement of Profit or Loss – Q3 2022
Statement of Profit or Loss – Q3 2022 Description % Jan - Sep 2022 % Jan - Sep 2021 Variance % Fav / Rupees in millions (Unfav) Sales 100 36,951 100 31,447 5,504 18 Cost of Sales 67 24,850 61 19,315 5,535 (29) Gross Profit 33 12,101 39 12,132 (31) 0 Selling and Distribution expenses 14 5,450 16 4,88
Slide 16: Statement of Financial Position – Sep 30, 2022
Statement of Financial Position – Sep 30, 2022 Sep Dec Description Sep 2022 Dec 2021 Variance Description Variance 2022 2021 Rupees in Millions % Rupees in Millions % Non-current assets Share capital and reserves Property, plant and equipment 11,199 10,006 1,193 12 Issued, subscribed and paid-up 979
Slide 17: Q&A
Q&A
Slide 18: Thank you
Thank you
Abbott Laboratories (Pakistan) — Investor Presentation (December 2022) on 6ix